Approximately 60 percent to 70 percent of diabetics suffer from the effects if peripheral neuropathy, with effects ranging from tingling in the arms and legs to unbearable pain.

The researchers urge parents to give their children water instead, and encourage regular physical activity and adequate sleep.

For the second straight year, Hospitals & Health Networks magazine has rated the U.Va. Health System as one of the nation’s “Most Wired” facilities.

Ebola infections can kill up to 90 percent of their victims, making them a potential biological weapon. But a class of drugs used for totally unrelated purposes may be able to stop the virus in its tracks.

The grant will allow U.Va. researchers to “rapidly determine” the ability of the drug “to improve the primary problem of reduced blood flow to the legs, which afflicts millions of patients with peripheral arterial disease,” says Dr. Brian Annex.

Scientists once thought that microRNAs were effectively junk, but new School of Medicine research indicates that one type of microRNA may be the key to treating peripheral artery disease.

For sufferers of diabetic retinopathy, a developing treatment could replace years of painful injections or destructive laser treatment.

The surprising finding could lead to new ways to battle conditions such as muscular dystrophy, facilitate healing after surgery and benefit athletes in their efforts to recover more quickly.

Doctors hope their discovery will help battle glioblastoma, the most common form of brain cancer in adults, which usually kills its victims within two or three years.

U.Va. researchers working as part of an NIH-funded consortium have identified the molecular structure of a protein whose mutations have been linked to early aging diseases and side effects for common HIV and AIDS drugs.